You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBrompheniramine
Accession NumberDB00835  (APRD00832)
TypeSmall Molecule
GroupsApproved
DescriptionHistamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. [PubChem]
Structure
Thumb
Synonyms
[3-(4-Bromo-phenyl)-3-pyridin-2-yl-propyl]-dimethyl-amine
1-(P-Bromophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
2-(P-Bromo-alpha-(2-dimethylaminoethyl)benzyl)pyridine
3-(4-Bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamine
3-(P-Bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine
BPN
Bromfeniramina
Brompheniramin
Bromphéniramine
Brompheniraminum
External Identifiers
  • AHR 1843
  • D 721
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dimegan Inj 10mg/mlliquid10 mgDexo Sa Labs Pharms1988-12-311997-05-30Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dimetane Elixir 2mg/5mlelixir2 mgoralWhitehall Robins Inc.1993-12-311997-08-07Canada
Dimetane Tab 4mgtablet4 mgoralWhitehall Robins Inc.1957-12-312000-07-26Canada
J-tan Pdliquid1 mg/mLoralJay Mac Pharmaceuticals Llc2007-05-29Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
BromfedWockhardt USA, LLC
BromfenexEthex Corporation
DimetaneWyeth
LodraneECR Pharmaceuticals
Brand mixtures
NameLabellerIngredients
7 Select Cold and Allergy Childrens7 Eleven
Alahist DMPoly Pharmaceuticals, Inc.
Altidec AAlternative Pharmacal Corporation
Altipres-BAlternative Pharmacal Corporation
Ap-hist DMAllegis Pharmaceuticals, LLC
Assured Childrens Cold and CoughBio Pharm, Inc.
Atuss DaAber Pharmaceuticals, Llc
Auro Tap Childrens Cold and AllergyAurohealth LLC
Auromine Childrens Cold and AllergyAurohealth LLC
Balahist DM SyrupBallay Pharmaceuticals, Inc.
Bio Dtuss DmxAdvanced Generic Corporation
Bio T Pres-BAdvanced Generic Corporation
Bpm-DM-phenCintex Services, Llc
Brohist DAllegis Pharmaceuticals, LLC
Brom TappRij Pharmaceutical Corporation
Brom Tapp DMRij Pharmaceutical Corporation
Bromfed DMClinical Solutions Wholesale
Bromfeddm DMPhysicians Total Care, Inc.
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan HydrobromidePaddock Laboratories, LLC
Brompheniramine Maleate, Pseudoephedrine Hydrochloride and DextromethorphanhydrobromideMorton Grove Pharmaceuticals, Inc.
Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan HydrobromideBoca Pharmacal, LLC
BrotappSilarx Pharmaceuticals, Inc
Brotapp DM Cold and CoughSilarx Pharmaceuticals, Inc
Brotapp PE-DM Cough and Cold LiquidSilarx Pharmaceutical, Inc
Brovex PebMcr American Pharmaceuticals, Inc.
Brovex Peb DMMcr American Pharmaceuticals, Inc.
Brovex PsbMcr American Pharmaceuticals, Inc.
Brovex Psb DMMcr American Pharmaceuticals, Inc.
Careone Childrens Cold and AllergyAmerican Sales Company
Careone Childrens Cold and CoughAmerican Sales Company
Centussin DhcCenturion Labs, Llc
Childrens Cold and AllergySelect Brand Dist.
Childrens Cold and Allergy ReliefSafeway, Inc.
Childrens Cold and CoughSelect Brand Dist.
Childrens Cold and Cough ReliefFamily Dollar (FAMILY WELLNESS)
Childrens Dibromm Cold and AllergySelect Brand Dist.
Childrens Dibromm Cold and CoughFreds Inc
Childrens Dimetapp Cold and AllergyRichmond Division of Wyeth
Childrens Dimetapp Cold and CoughRichmond Division of Wyeth
Childrens Metapp DaytimeGuardian Drug Company
Childrens Wal Tap DMWalgreen Company
Childrens Wal Tap DM Cough and ColdWalgreen Company
Childrens Wal Tap Elixer Cold and AllergyWalgreens
Cold & Allergy Relief - LiqStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Cold and Allergy ChildrensMeijer Distribution Inc
Cold and CoughH E B
Cold and Cough ChildrensCVS Pharmacy
Cold and Cough DMPublix Super Markets Inc
Cold LiquidTanta Pharmaceuticals Inc
Cold Liquid Grape FlavourPharmetics (2011) Inc
Cold ReliefPerrigo International
Cold Relief DMPerrigo International
Cold SyrupJamp Pharma Corporation
Cough, Cold & Allergy ReliefStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Daytime Cold and Cough and Nighttime Cold and Congestion ChildrensTarget Corporation
Decongestant Antihistaminic SyrupPharmascience Inc
Dg Health Cold and Allergy ChildrensDolgencorp Inc
Dibromm Cold and Allergy ChildrensQUALITY CHOICE (Chain Drug Marketing Association)
Dibromm DMMajor Pharmaceuticals
Dibromm With PEMajor Pharmaceuticals
Dicel CDCentrix Pharmaceutical
DimaphenMajor Pharmaceuticals
Dimaphen DMMajor Pharmaceuticals
Dimetane DxCreekwood Pharmaceuticals Inc.
Dimetane Expectorant CPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetane Expectorant DcPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetane Expectorant LiqWhitehall Robins Inc.
Dimetane Expectorant-C SyrWhitehall Robins Inc.
Dimetane Expectorant-DC SyrWhitehall Robins Inc.
DimetappPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetapp Chewable TabletsWhitehall Robins Inc.
Dimetapp Chewables for KidsPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetapp Children's Cold & Allergy TabletsWhitehall Robins Inc.
Dimetapp Children's Cold & FeverWhitehall Robins Inc.
Dimetapp ClearWhitehall Robins Inc.
Dimetapp Cough & Cold Liqui-gels - CapWhitehall Robins Inc.
Dimetapp Cough, Cold & FluWhitehall Robins Inc.
Dimetapp DM Cough & ColdPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetapp DM ElixirWhitehall Robins Inc.
Dimetapp DM TabWhitehall Robins Inc.
Dimetapp ElixirWhitehall Robins Inc.
Dimetapp ExtentabsWhitehall Robins Inc.
Dimetapp Extra StrengthPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetapp Extra Strength DM Cough & ColdPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetapp Liqui-gels CapWhitehall Robins Inc.
Dimetapp Oral Infant Cold and Fever DropsWyeth Consumer Healthcare Inc.
Dimetapp Oral Infant Cold DropsWyeth Consumer Healthcare Inc.
Dimetapp Oral Infant DropsWhitehall Robins Inc.
Dimetapp TabWhitehall Robins Inc.
Dimetapp-CPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetapp-C SyrWhitehall Robins Inc.
DM Cough and Cold LiquidTanta Pharmaceuticals Inc
DM Cough and Cold Liquid Cherry FlavourPharmetics (2011) Inc
DM Cough and Cold ReliefPharmetics (2011) Inc
DM Cough and Cold SyrupJamp Pharma Corporation
Endacof DMLarken Laboratories, Inc.
Equaline Childrens Cold and CoughSupervalu Inc
Equate Childrens Cold and CoughWal Mart Stores Inc
Extra Strength Cold LiquidTanta Pharmaceuticals Inc
Extra Strength Cold SyrupJamp Pharma Corporation
Extra Strength DM Cough and Cold LiquidTanta Pharmaceuticals Inc
Extra Strength DM Cough and Cold SyrupJamp Pharma Corporation
Glenmax PebGlendale Inc
Glenmax Peb DMGlendale Inc
Glenmax Peb DM ForteGlendale Inc
Good Neighbor Pharmacy Cold and Allergy ChildrensAmerisource Bergen
Good Neighbor Pharmacy Cold and CoughAmerisource Bergen
Good Sense Childrens Cold and AllergyL. Perrigo Company
Good Sense Childrens Cold and Cough ElixirL Perrigo Company
Health Mart Cold and Allergy ChildrensMc Kesson
Health Mart Cold and Cough ChildrensMc Kesson
Healthy Accents Childrens Cold and CoughDZA Brands LLC
Healthy Accents Cold and Allergy ChildrensDZA Brands LLC
Healthy Accents Cold and Cough DMDZA Brands LLC
J-cof DhcJay Mac Pharmaceuticals
J-tan D PdJay Mac Pharmaceuticals Llc
Kids Cold Chewable TabletsTanta Pharmaceuticals Inc
Leader Childrens Cold and AllergyCardinal Health
Leader Childrens Cold and CoughCardinal Health
Lodrane DECR Pharmaceuticals
Lohist DMLarken Laboratories, Inc.
Lohist PebLarken Laboratories, Inc.
Lohist Peb DMLarken Laboratories, Inc.
M-end PER.A. Mc Neil Company
M-end WcR.A. Mc Neil Company
Mar-cof BPMarnel Pharmaceutcals, Inc.
Neo DMLaser Pharmaceuticals Llc
Niva-hist DMNivagen Pharmaceuticals, Inc.
Oral Infant Cold DropsTanta Pharmaceuticals Inc
Pharmetapp ElixirTherapex Division De E Z Em Canada Inc
PluratussCreekwood Pharmaceutical, Inc.
Poly-tussin AcPoly Pharmaceuticals, Inc.
Presgen BKramer Novis
Q Tapp Cold and AllergyQualitest Pharmaceuticals
Q Tapp Cold and CoughQualitest Pharmaceuticals
Q-tappQualitest Pharmaceuticals
Q-tapp DM ElixirQualitest Pharmaceuticals
Relcof DMBurel Pharmaceuticals, Inc
Relhist BPBurel Pharmaceuticals, Inc
Robitussin Children's ColdPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robitussin Children's Cough & Cold BedtimePfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Rompe Pecho Sf FluEfficient Laboratories Inc
Ru-hist DAllegis Pharmaceuticals, LLC
Runny Nose and CoughAccudial Pharmaceutical, Inc.
Rx Act Cold and Allergy ChildrensH E B
RydexCenturion Labs
Rynex DMEDWARDS PHARMACEUTICALS, INC.
Rynex PEEDWARDS PHARMACEUTICALS, INC.
Rynex PseEDWARDS PHARMACEUTICALS, INC.
Shoprite Childrens Cold and AllergyWakefern Food Corporation
Shoprite Childrens Cold and CoughWakefern Food Corporation
Signature Care Childrens Cold and CoughSafeway
Smart Sense Cold and Allergy ChildrensKmart Corporation
Smart Sense Cold and CoughKmart Corporation
StaflexMagna Pharmaceuticals, Inc.
Sunmark Cold and Allergy ChildrensMc Kesson
Sunmark Cold and Cough DM ChildrensMc Kesson
Tantapp ElixirTanta Pharmaceuticals Inc
Topcare Childrens Cold and Allergy ElixerTopco Associates LLC
Topcare Childrens Cold and Cough ElixirTopco Associates LLC
Triaminic Cold and AllergyNovartis Consumer Health, Inc.
Tussi Pres BKramer Novis
Up and Up Childrens Cold and CoughTarget Corporation
Vazobid-PDWraser Pharmaceuticals
Wal Tap Elixir ChildrensWalgreen Company
Salts
Name/CASStructureProperties
Brompheniramine maleate
ThumbNot applicableDBSALT000940
Categories
UNIIH57G17P2FN
CAS number86-22-6
WeightAverage: 319.239
Monoisotopic: 318.073161265
Chemical FormulaC16H19BrN2
InChI KeyInChIKey=ZDIGNSYAACHWNL-UHFFFAOYSA-N
InChI
InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3
IUPAC Name
[3-(4-bromophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
SMILES
CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPheniramines
Direct ParentPheniramines
Alternative Parents
Substituents
  • Pheniramine
  • Phenylpropylamine
  • Aralkylamine
  • Halobenzene
  • Bromobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl bromide
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing.
PharmacodynamicsBrompheniramine is an antihistaminergic medication of the propylamine class. It is a first-generation antihistamine. In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Brompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
Mechanism of actionBrompheniramine works by acting as an antagonist of the H1 histamine receptors. It also functions as a moderately effective anticholingeric agent, likely an antimuscarinic agent similar to other common antihistamines such as diphenhydramine. Its effects on the cholinergic system may include side-effects such as drowsiness, sedation, dry mouth, dry throat, blurred vision, and increased heart rate.
Related Articles
AbsorptionAntihistamines are well absorbed from the gastrointestinal tract after oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic (cytochrome P-450 system), some renal.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral, rat: LD50 = 318 mg/kg. Signs of overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9648
Blood Brain Barrier+0.9576
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.6242
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.93
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.8345
CYP450 2D6 substrateSubstrate0.8346
CYP450 3A4 substrateSubstrate0.5898
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8398
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7748
Ames testNon AMES toxic0.9351
CarcinogenicityNon-carcinogens0.9349
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.0758 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9121
hERG inhibition (predictor II)Inhibitor0.7207
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alpharma us pharmaceuticals division
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Usl pharma inc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Wyeth consumer healthcare
  • Barr laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Newtron pharmaceuticals inc
  • Nexgen pharma inc
  • Par pharmaceutical inc
  • Pioneer pharmaceuticals inc
  • Sandoz inc
  • Vitarine pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedoral
Tablet, chewableoral
Liquidoral
Kit
Liquid10 mg
Elixiroral2 mg
Tabletoral4 mg
Tablet (chewable)oral
Tablet (extended-release)oral
Dropsoral
Solutionoral
Elixiroral
Liquidoral1 mg/mL
Capsuleoral
Tabletoral
Syruporal
Prices
Unit descriptionCostUnit
Brompheniramine maleate powder9.83USD g
Brovex ct 12 mg tablet chew1.58USD tablet
Brompheniramine 12 mg tablet chew1.42USD tablet
Bromfenex-pd capsule sa0.56USD capsule
Bromfed-dm cough syrup0.21USD ml
Brom-pseud-dm syrup0.14USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point149.5 °C at 5.00E-01 mm HgPhysProp
water solubilityFreely soluble (maleate salt)Not Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP3.63ALOGPS
logP3.75ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)9.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area16.13 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity83.67 m3·mol-1ChemAxon
Polarizability32.08 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)splash10-014i-4954000000-f0a4889ab8cd0d5dcaccView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)splash10-00di-0090000000-02a74d4d4927d8e443aaView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)splash10-014i-0920000000-ad3d20cb0f1b7362fbc3View in MoNA
MSMass Spectrum (Electron Ionization)splash10-0002-5490000000-9c3b804de0b552198b85View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Sperber, N., Papa, D. and Schwenk, E.; US. Patent 2,567,245; September 11, 1951; assigned
to Schering Corporation.
Sperber, N., Papa, D. and Schwenk, E.; U.S. Patent 2,676,964: April 27,1954; assigned to
Schering Corporation.

General ReferencesNot Available
External Links
ATC CodesR06AB51R06AB01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.1 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Brompheniramine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Brompheniramine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Brompheniramine.
AbirateroneThe serum concentration of Brompheniramine can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Brompheniramine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Brompheniramine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Brompheniramine.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brompheniramine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Brompheniramine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Brompheniramine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Brompheniramine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Brompheniramine.
AmiodaroneThe metabolism of Brompheniramine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Brompheniramine.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Brompheniramine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Brompheniramine.
AmoxapineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Brompheniramine.
AmphetamineAmphetamine may decrease the sedative activities of Brompheniramine.
AprepitantThe serum concentration of Brompheniramine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brompheniramine.
ArmodafinilThe metabolism of Brompheniramine can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Brompheniramine can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Brompheniramine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Brompheniramine.
AtazanavirThe metabolism of Brompheniramine can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Brompheniramine can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Brompheniramine.
AzelastineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Brompheniramine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Brompheniramine.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Brompheniramine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Brompheniramine.
BenzphetamineBenzphetamine may decrease the sedative activities of Brompheniramine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Brompheniramine.
Benzylpenicilloyl PolylysineBrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Brompheniramine.
BetaxololThe metabolism of Brompheniramine can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Brompheniramine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Brompheniramine can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Brompheniramine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Brompheniramine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
BrimonidineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Brompheniramine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Brompheniramine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Brompheniramine.
BupropionThe metabolism of Brompheniramine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Brompheniramine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Brompheniramine.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Brompheniramine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Brompheniramine.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Brompheniramine.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Brompheniramine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brompheniramine.
CapecitabineThe metabolism of Brompheniramine can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brompheniramine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Brompheniramine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Brompheniramine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brompheniramine.
CelecoxibThe metabolism of Brompheniramine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Brompheniramine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Brompheniramine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Brompheniramine.
ChloramphenicolThe metabolism of Brompheniramine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Brompheniramine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Brompheniramine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brompheniramine.
ChloroquineThe metabolism of Brompheniramine can be decreased when combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Brompheniramine.
ChlorpromazineThe metabolism of Brompheniramine can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brompheniramine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brompheniramine.
CholecalciferolThe metabolism of Brompheniramine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Brompheniramine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Brompheniramine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brompheniramine.
CitalopramThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Citalopram.
CitalopramThe metabolism of Brompheniramine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Brompheniramine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Brompheniramine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Brompheniramine.
ClobazamThe metabolism of Brompheniramine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Brompheniramine.
ClomipramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clomipramine.
ClomipramineThe metabolism of Brompheniramine can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Brompheniramine.
ClopidogrelThe metabolism of Brompheniramine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Brompheniramine.
ClotrimazoleThe metabolism of Brompheniramine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Brompheniramine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Clozapine.
CobicistatThe serum concentration of Brompheniramine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Brompheniramine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Brompheniramine.
ConivaptanThe serum concentration of Brompheniramine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Brompheniramine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brompheniramine.
CyclosporineThe metabolism of Brompheniramine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Brompheniramine.
Cyproterone acetateThe serum concentration of Brompheniramine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Brompheniramine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Brompheniramine.
DapoxetineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dapoxetine.
DarifenacinThe metabolism of Brompheniramine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Brompheniramine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Brompheniramine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Brompheniramine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Brompheniramine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Brompheniramine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Brompheniramine.
DesipramineThe metabolism of Brompheniramine can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Brompheniramine.
DexamethasoneThe serum concentration of Brompheniramine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Brompheniramine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Brompheniramine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Brompheniramine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Brompheniramine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Brompheniramine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Brompheniramine.
DifenoxinThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Brompheniramine.
DihydroergotamineThe metabolism of Brompheniramine can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Brompheniramine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Brompheniramine.
DiltiazemThe metabolism of Brompheniramine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Brompheniramine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Brompheniramine.
DisulfiramThe metabolism of Brompheniramine can be decreased when combined with Disulfiram.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Brompheniramine.
DoxepinThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Doxepin.
DoxorubicinThe metabolism of Brompheniramine can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Brompheniramine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
DoxylamineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Brompheniramine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
DronedaroneThe metabolism of Brompheniramine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Brompheniramine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Brompheniramine.
DuloxetineThe metabolism of Brompheniramine can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Brompheniramine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Brompheniramine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Brompheniramine.
EfavirenzThe serum concentration of Brompheniramine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Efavirenz.
EliglustatThe metabolism of Brompheniramine can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Brompheniramine.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Brompheniramine.
EnzalutamideThe serum concentration of Brompheniramine can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Brompheniramine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Brompheniramine can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Brompheniramine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Brompheniramine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Brompheniramine.
EthanolBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Brompheniramine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Brompheniramine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Brompheniramine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Brompheniramine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Brompheniramine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Brompheniramine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Brompheniramine.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Brompheniramine.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Brompheniramine.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Brompheniramine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Brompheniramine.
EtoperidoneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Brompheniramine.
EtravirineThe serum concentration of Brompheniramine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Felbamate.
FelodipineThe metabolism of Brompheniramine can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Brompheniramine.
FenfluramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Brompheniramine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Brompheniramine.
FexofenadineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Flibanserin.
FloxuridineThe metabolism of Brompheniramine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Brompheniramine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Brompheniramine.
FlunarizineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Brompheniramine.
FluorouracilThe metabolism of Brompheniramine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fluoxetine.
FluoxetineThe metabolism of Brompheniramine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Brompheniramine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brompheniramine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Brompheniramine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Brompheniramine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Brompheniramine.
FluvastatinThe metabolism of Brompheniramine can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Brompheniramine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Brompheniramine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Brompheniramine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Brompheniramine.
Fusidic AcidThe serum concentration of Brompheniramine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Brompheniramine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Brompheniramine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Brompheniramine.
GemfibrozilThe metabolism of Brompheniramine can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Brompheniramine.
GuanfacineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Brompheniramine.
HaloperidolThe metabolism of Brompheniramine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Brompheniramine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Brompheniramine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brompheniramine.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Brompheniramine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Brompheniramine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Brompheniramine.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Brompheniramine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
HydroxyzineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Brompheniramine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Iloperidone.
ImatinibThe metabolism of Brompheniramine can be decreased when combined with Imatinib.
ImipramineThe metabolism of Brompheniramine can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Indalpine.
IndinavirThe metabolism of Brompheniramine can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Brompheniramine can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Brompheniramine can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Brompheniramine.
IsoniazidThe metabolism of Brompheniramine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Brompheniramine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Brompheniramine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Brompheniramine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brompheniramine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brompheniramine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Brompheniramine.
KetoconazoleThe metabolism of Brompheniramine can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Brompheniramine.
LapatinibThe metabolism of Brompheniramine can be decreased when combined with Lapatinib.
LeflunomideThe metabolism of Brompheniramine can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Brompheniramine.
LevocabastineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Brompheniramine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Brompheniramine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Brompheniramine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Brompheniramine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Brompheniramine.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Brompheniramine.
LopinavirThe metabolism of Brompheniramine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Brompheniramine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Brompheniramine.
LorcaserinThe metabolism of Brompheniramine can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Brompheniramine can be decreased when combined with Losartan.
LovastatinThe metabolism of Brompheniramine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Brompheniramine.
Lu AA21004The risk or severity of adverse effects can be increased when Brompheniramine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Brompheniramine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Brompheniramine can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Brompheniramine can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Brompheniramine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Brompheniramine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Brompheniramine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Brompheniramine.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Brompheniramine.
MephentermineMephentermine may decrease the sedative activities of Brompheniramine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brompheniramine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brompheniramine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Brompheniramine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brompheniramine.
MethadoneThe metabolism of Brompheniramine can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Brompheniramine.
MethamphetamineMethamphetamine may decrease the sedative activities of Brompheniramine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brompheniramine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Brompheniramine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brompheniramine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Brompheniramine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Brompheniramine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Brompheniramine.
MethsuximideThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Brompheniramine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Brompheniramine.
MetoprololThe metabolism of Brompheniramine can be decreased when combined with Metoprolol.
MetyrosineBrompheniramine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Brompheniramine.
MifepristoneThe metabolism of Brompheniramine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
MirabegronThe metabolism of Brompheniramine can be decreased when combined with Mirabegron.
MirtazapineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Brompheniramine.
MitotaneThe serum concentration of Brompheniramine can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Brompheniramine can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Brompheniramine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Brompheniramine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Brompheniramine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.
NabiloneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Nabilone.
NafcillinThe serum concentration of Brompheniramine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Brompheniramine.
NefazodoneThe metabolism of Brompheniramine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Brompheniramine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Brompheniramine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Brompheniramine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Brompheniramine can be decreased when combined with Nicardipine.
NicotineThe metabolism of Brompheniramine can be decreased when combined with Nicotine.
NilotinibThe metabolism of Brompheniramine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Brompheniramine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Brompheniramine.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Brompheniramine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Brompheniramine.
OlanzapineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Olanzapine.
OlaparibThe metabolism of Brompheniramine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Brompheniramine.
OmeprazoleThe metabolism of Brompheniramine can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Brompheniramine.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Brompheniramine.
OrphenadrineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Brompheniramine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Brompheniramine.
OsimertinibThe serum concentration of Brompheniramine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brompheniramine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Brompheniramine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Brompheniramine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Brompheniramine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Brompheniramine.
PalbociclibThe serum concentration of Brompheniramine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Brompheniramine.
PanobinostatThe metabolism of Brompheniramine can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Brompheniramine can be decreased when combined with Pantoprazole.
ParaldehydeBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Brompheniramine.
ParoxetineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Paroxetine.
ParoxetineThe metabolism of Brompheniramine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Brompheniramine can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Brompheniramine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Brompheniramine.
PerampanelThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Brompheniramine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Brompheniramine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Brompheniramine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Brompheniramine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Brompheniramine.
PhenterminePhentermine may decrease the sedative activities of Brompheniramine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Brompheniramine.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Brompheniramine.
PioglitazoneThe metabolism of Brompheniramine can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Brompheniramine.
PipotiazineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pomalidomide.
PosaconazoleThe metabolism of Brompheniramine can be decreased when combined with Posaconazole.
PramipexoleBrompheniramine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Brompheniramine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Brompheniramine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Brompheniramine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Brompheniramine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Brompheniramine.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Brompheniramine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brompheniramine.
PromazineThe metabolism of Brompheniramine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Brompheniramine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Brompheniramine.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Brompheniramine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brompheniramine.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Brompheniramine.
PyrimethamineThe metabolism of Brompheniramine can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Brompheniramine can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brompheniramine.
QuinidineThe metabolism of Brompheniramine can be decreased when combined with Quinidine.
QuinineThe metabolism of Brompheniramine can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Brompheniramine can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ramelteon.
RanolazineThe metabolism of Brompheniramine can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brompheniramine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Brompheniramine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Brompheniramine.
RifabutinThe metabolism of Brompheniramine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Brompheniramine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Brompheniramine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Brompheniramine.
RitonavirThe metabolism of Brompheniramine can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Brompheniramine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Brompheniramine.
RopiniroleBrompheniramine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Brompheniramine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Brompheniramine.
RosiglitazoneThe metabolism of Brompheniramine can be decreased when combined with Rosiglitazone.
RotigotineBrompheniramine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Brompheniramine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Brompheniramine.
SaquinavirThe metabolism of Brompheniramine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Brompheniramine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brompheniramine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Brompheniramine.
SertralineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Sertraline.
SertralineThe metabolism of Brompheniramine can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brompheniramine.
SildenafilThe metabolism of Brompheniramine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Brompheniramine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Brompheniramine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Brompheniramine.
SorafenibThe metabolism of Brompheniramine can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Brompheniramine can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brompheniramine.
SulfadiazineThe metabolism of Brompheniramine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Brompheniramine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Brompheniramine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Brompheniramine.
SuvorexantThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Suvorexant.
TamoxifenThe metabolism of Brompheniramine can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tasimelteon.
TelaprevirThe metabolism of Brompheniramine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Brompheniramine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Brompheniramine.
TerbinafineThe metabolism of Brompheniramine can be decreased when combined with Terbinafine.
TeriflunomideThe metabolism of Brompheniramine can be decreased when combined with Teriflunomide.
TetrabenazineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Brompheniramine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Brompheniramine.
ThalidomideBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Brompheniramine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brompheniramine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Brompheniramine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Brompheniramine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Brompheniramine.
ThiotepaThe metabolism of Brompheniramine can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Brompheniramine.
TiagabineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tiagabine.
TicagrelorThe metabolism of Brompheniramine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Brompheniramine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Brompheniramine.
TipranavirThe metabolism of Brompheniramine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Brompheniramine.
TocilizumabThe serum concentration of Brompheniramine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Brompheniramine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Brompheniramine.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Brompheniramine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Brompheniramine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Brompheniramine.
TranylcypromineThe metabolism of Brompheniramine can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Brompheniramine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Brompheniramine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Brompheniramine.
TrimethoprimThe metabolism of Brompheniramine can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Brompheniramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Brompheniramine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Brompheniramine.
ValsartanThe metabolism of Brompheniramine can be decreased when combined with Valsartan.
VenlafaxineThe metabolism of Brompheniramine can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Brompheniramine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Vilazodone.
VoriconazoleThe metabolism of Brompheniramine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Brompheniramine.
ZafirlukastThe metabolism of Brompheniramine can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brompheniramine.
ZiconotideThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Zimelidine.
ZiprasidoneThe metabolism of Brompheniramine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Brompheniramine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Brompheniramine.
ZonisamideThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Brompheniramine.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Brompheniramine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Brompheniramine.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Bokesoy TA, Onaran HO: Atypical Schild plots with histamine H1 receptor agonists and antagonists in the rabbit aorta. Eur J Pharmacol. 1991 May 2;197(1):49-56. [PubMed:1680053 ]
  2. Onaran HO, Bokesoy TA: Kinetics of antagonism at histamine-H1 receptors in isolated rabbit arteries. Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):316-23. [PubMed:1970615 ]
  3. Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75. [PubMed:7714410 ]
  4. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  5. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Yasuda SU, Yasuda RP: Affinities of brompheniramine, chlorpheniramine, and terfenadine at the five human muscarinic cholinergic receptor subtypes. Pharmacotherapy. 1999 Apr;19(4):447-51. [PubMed:10212017 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23